Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Micelle-Forming Block Copolymers Tailored for Inhibition of P-gp-Mediated Multidrug Resistance: Structure to Activity Relationship.

Braunová A, Kaňa M, Kudláčová J, Kostka L, Bouček J, Betka J, Šírová M, Etrych T.

Pharmaceutics. 2019 Nov 5;11(11). pii: E579. doi: 10.3390/pharmaceutics11110579.

2.

Bloodstream Stability Predetermines the Antitumor Efficacy of Micellar Polymer-Doxorubicin Drug Conjugates with pH-Triggered Drug Release.

Chytil P, Šírová M, Kudláčová J, Říhová B, Ulbrich K, Etrych T.

Mol Pharm. 2018 Sep 4;15(9):3654-3663. doi: 10.1021/acs.molpharmaceut.8b00156. Epub 2018 Mar 21.

PMID:
29543465
3.

Polymer donors of nitric oxide improve the treatment of experimental solid tumours with nanosized polymer therapeutics.

Šírová M, Horková V, Etrych T, Chytil P, Říhová B, Studenovský M.

J Drug Target. 2017 Nov - Dec;25(9-10):796-808. doi: 10.1080/1061186X.2017.1358724. Epub 2017 Aug 7.

PMID:
28726521
4.

The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.

Šírová M, Strohalm J, Chytil P, Lidický O, Tomala J, Říhová B, Etrych T.

J Control Release. 2017 Jan 28;246:1-11. doi: 10.1016/j.jconrel.2016.12.004. Epub 2016 Dec 6.

PMID:
27940304
5.

Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.

Braunová A, Kostka L, Sivák L, Cuchalová L, Hvězdová Z, Laga R, Filippov S, Černoch P, Pechar M, Janoušková O, Šírová M, Etrych T.

J Control Release. 2017 Jan 10;245:41-51. doi: 10.1016/j.jconrel.2016.11.020. Epub 2016 Nov 18.

PMID:
27871991
6.

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.

Tomalova B, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M.

J Control Release. 2016 Feb 10;223:1-10. doi: 10.1016/j.jconrel.2015.12.023. Epub 2015 Dec 18.

PMID:
26708020
7.

Immunocompatibility evaluation of hydrogel-coated polyimide implants for applications in regenerative medicine.

Sirova M, Van Vlierberghe S, Matyasova V, Rossmann P, Schacht E, Dubruel P, Rihova B.

J Biomed Mater Res A. 2014 Jun;102(6):1982-90. doi: 10.1002/jbm.a.34873. Epub 2013 Jul 30.

PMID:
23852806
8.

Dimerization of an immunoactivating peptide derived from mycobacterial hsp65 using N-hydroxysuccinimide based bifunctional reagents is critical for its antitumor properties.

Bezouška K, Kubínková Z, Stříbný J, Volfová B, Pompach P, Kuzma M, Šírová M, Říhová B.

Bioconjug Chem. 2012 Oct 17;23(10):2032-41. doi: 10.1021/bc300056x. Epub 2012 Sep 28. Retraction in: Bioconjug Chem. 2014 Feb 19;25(2):451.

PMID:
22988810
9.

HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity.

Etrych T, Subr V, Strohalm J, Sírová M, Ríhová B, Ulbrich K.

J Control Release. 2012 Dec 28;164(3):346-54. doi: 10.1016/j.jconrel.2012.06.029. Epub 2012 Jun 30.

PMID:
22759979
10.

Synergistic effect of EMF-BEMER-type pulsed weak electromagnetic field and HPMA-bound doxorubicin on mouse EL4 T-cell lymphoma.

Říhová B, Etrych T, Šírová M, Tomala J, Ulbrich K, Kovář M.

J Drug Target. 2011 Dec;19(10):890-9. doi: 10.3109/1061186X.2011.622403. Epub 2011 Oct 10.

PMID:
21981636
11.

Implantation of ultrathin, biofunctionalized polyimide membranes into the subretinal space of rats.

Julien S, Peters T, Ziemssen F, Arango-Gonzalez B, Beck S, Thielecke H, Büth H, Van Vlierberghe S, Sirova M, Rossmann P, Rihova B, Schacht E, Dubruel P, Zrenner E, Schraermeyer U.

Biomaterials. 2011 Jun;32(16):3890-8. doi: 10.1016/j.biomaterials.2011.02.016.

PMID:
21388675
12.

Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of N-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity.

Tomala J, Chmelova H, Strohalm J, Ulbrich K, Sirova M, Rihova B, Kovar M.

Int J Cancer. 2011 Oct 15;129(8):2002-12. doi: 10.1002/ijc.25859. Epub 2011 Apr 13.

13.

HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release.

Etrych T, Sírová M, Starovoytova L, Ríhová B, Ulbrich K.

Mol Pharm. 2010 Aug 2;7(4):1015-26. doi: 10.1021/mp100119f.

PMID:
20518512
14.

Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.

Sirova M, Mrkvan T, Etrych T, Chytil P, Rossmann P, Ibrahimova M, Kovar L, Ulbrich K, Rihova B.

Pharm Res. 2010 Jan;27(1):200-8. doi: 10.1007/s11095-009-9999-7. Epub 2009 Nov 6.

PMID:
19894105
15.

Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.

Kovar M, Tomala J, Chmelova H, Kovar L, Mrkvan T, Joskova R, Zakostelska Z, Etrych T, Strohalm J, Ulbrich K, Sirova M, Rihova B.

Cancer Res. 2008 Dec 1;68(23):9875-83. doi: 10.1158/0008-5472.CAN-08-1979.

16.

Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.

Etrych T, Chytil P, Mrkvan T, Sírová M, Ríhová B, Ulbrich K.

J Control Release. 2008 Dec 18;132(3):184-92. doi: 10.1016/j.jconrel.2008.04.017. Epub 2008 Apr 29.

PMID:
18534705
17.

Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.

Chytil P, Etrych T, Konák C, Sírová M, Mrkvan T, Ríhová B, Ulbrich K.

J Control Release. 2006 Sep 28;115(1):26-36. Epub 2006 Jun 30.

PMID:
16899320
18.

Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice.

Sirova M, Strohalm J, Subr V, Plocova D, Rossmann P, Mrkvan T, Ulbrich K, Rihova B.

Cancer Immunol Immunother. 2007 Jan;56(1):35-47. Epub 2006 Apr 25.

PMID:
16636810
19.

Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.

Mrkvan T, Sirova M, Etrych T, Chytil P, Strohalm J, Plocova D, Ulbrich K, Rihova B.

J Control Release. 2005 Dec 10;110(1):119-29. Epub 2005 Nov 2.

PMID:
16269198
20.

Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data.

Ríhová B, Strohalm J, Prausová J, Kubácková K, Jelínková M, Rozprimová L, Sírová M, Plocová D, Etrych T, Subr V, Mrkvan T, Kovár M, Ulbrich K.

J Control Release. 2003 Aug 28;91(1-2):1-16.

PMID:
12932633

Supplemental Content

Loading ...
Support Center